Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 17/20 | 0.49 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.49 |
| ▸ | PTGFR | P43088 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21225843 | 0.92 | PTGER4 (0.42) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL21232942 | 0.92 | PDE2A (0.43) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL29225608 | 0.90 | SLC6A9 (0.44) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL21225421 | 0.82 | PTGER4 (0.51) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL21225765 | 0.81 | PTGER4 (0.49) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL21225068 | 0.81 | PTGER4 (0.49) | PTGER4PTGDRPTGER2TBXA2RPTGER1 | |
| SCHEMBL21225779 | 0.81 | PTGER4 (0.50) | PTGER4PTGDRPTGER2 | |
| SCHEMBL21225778 | 0.81 | PTGER4 (0.50) | PTGER4PTGDRPTGER2 | |
| SCHEMBL21225736 | 0.80 | SCN9A (0.41) | PTGER3 | |
| SCHEMBL30740359 | 0.80 | SCN9A (0.41) | PTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936138-B | Heterobicyclic compounds as EP4 receptor antagonists | 深圳市原力生命科学有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-111936138-A | Heterobicyclic compounds as EP4 receptor antagonists | 深圳市原力生命科学有限公司 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019152982-A1 | HETEROBICYCLIC COMPOUNDS AS EP4 ANTAGONISTS | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019152982-A1 | HETEROBICYCLIC COMPOUNDS AS EP4 ANTAGONISTS | SHENZHEN IONOVA LIFE SCIENCE CO., LTD. (CN) | 2019-08-08 | — | — | WO | disclosed |